Sur­vey says: Brex­it blues hit bio­phar­ma as in­dus­try ex­ecs over­whelm­ing­ly turn thumbs down on the UK's fu­ture

What­ev­er your thoughts about Brex­it — for or against — the po­lit­i­cal angst that it has pro­voked in the UK in re­cent months has trig­gered a steady ero­sion in the glob­al phar­ma in­dus­try’s opin­ion of the coun­try as an at­trac­tive place to do re­search and man­u­fac­tur­ing. And in­side the UK, the dai­ly din of con­tro­ver­sy has pro­voked a clear cri­sis of con­fi­dence in the in­dus­try’s fu­ture.

Glob­al­Da­ta has been sur­vey­ing a mix of phar­ma ex­ecs around the world each quar­ter this year. And af­ter about half of their British re­spon­dents had pro­vid­ed a thumbs up ini­tial­ly, on­ly 17% were ready to af­firm that the UK will re­main an at­trac­tive des­ti­na­tion for R&D/man­u­fac­tur­ing work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.